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Interleukin 6 (IL-6) is a multifunctional regulator of immune
responses, haemopoiesis, and acute phase reactions, as well as of cell
growth and differentiation (Hirano, 1994). In addition, IL-6 de-regu-
lation is also involved in a variety of diseases, including malignan-
cies (plasmacytoma/myeloma, leukaemia/lymphoma, melanoma,
Kaposi’s sarcoma, renal cell carcinoma, salivary gland carcinoma),
(Michiel et al, 1992). Production of IL-6 is up-regulated by cytokines
such as IL-1 and tumour necrosis factor (TNF) (Hirano, 1994) as
well as by certain oncogenes including N-ras (Castelli et al, 1994). In
addition, it has been shown that the production of IL-6 is modulated
by hormones, such as steroids (Ray and Prefortaine et al, 1994).
These observations suggest that different pathways could lead to the
altered expression of this cytokine.
Since cytokines seem to play an important role both in physiolog-
ical and pathological conditions, we have previously analysed the
cytokine pattern expression in cultures of human mammary epithe-
lial cells (MEC) obtained from healthy donors as well as in cultures
of immortalized and oncogene-transformed MEC. IL-6 expression
has also been studied in sections obtained from normal mammary
glands, and non-invasive and invasive carcinomas. Our results have
shown that normal MEC produce IL-6 and IL-8 together with a non-
secreted form of TNF (Basolo et al, 1993a). In addition, we found
that MEC transformation by different oncogenes (c-Ha-ras, c-erb-
B2, simian virus 40 T large antigen) is frequently associated with the
loss of IL-6 production and responsiveness to exogenous IL-6
(Basolo et al, 1993b; Basolo et al, 1996a).
Immunohistochemical studies have also shown that, as
compared to normal tissue and to in situ lesions, expression of
immunoreactive IL-6 in human mammary tissue is significantly
reduced in invasive ductal carcinoma (Basolo et al, 1996b).
Parallel in vitro studies partially supported the in vivo findings:
IL-6 expression was significantly reduced in cultures derived from
both ductal carcinoma and peritumoral tissue. All these reports
suggest that alterations of IL-6 pathways are a frequent event in
human breast tumorigenesis.
Although there is some information on the possible role of IL-6
in plasmacytoma/myeloma, leukaemia/lymphoma, melanoma,
Kaposi’s sarcoma, renal cell and salivary gland carcinomas
(Hirano, 1994; Gandour-Edwards et al, 1995a; Silvani et al, 1995)
no data are available on the correlation between IL-6 expression
and the clinico-pathological variables in mammary neoplasia. This
has prompted us to study the expression of IL-6 in a series of
breast carcinomas and to correlate the positivity for this cytokine
to clinico-pathological and biological parameters.
MATERIALS AND METHODS
Patients
For this study, 149 cases were chosen among the patients diag-
nosed at the Department of Oncology of the S Chiara Hospital,
University of Pisa. Selected patients had not received any anti-
neoplastic treatments before surgery.
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After fixation in 10% formalin, processing and paraffin embed-
ding, 3- to 5 mm-thick sections were prepared. Sections were
dewaxed and dehydrated, and the endogenous peroxidase activity
was blocked by incubation for 15 min with 0.3% hydrogen
peroxide in methanol. Sections were stained with two different
anti-IL-6 antibodies (rabbit polyclonal antibody and IL-6 mouse
IgG1 monoclonal antibody, Genzyme Co., Cambridge, MA, USA;
product codes LP-716 and 1618-01), p53 mouse IgG2b mono-
clonal antibody (DAKO A/S, Denmark; clone DO7). Antibody
dilutions (1:100 or 1:500) were incubated overnight; immuno-
reactivity was revealed with the avidin–biotin immunoperoxidase
complex technique (Vector Elite ABC kit; Vector Laboratories,
Burlingame, CA, USA). Sections were scored independently by
two pathologists (GF and FB) using the following method: (a) the
intensity of staining for each antigen was scored from 0 to 3 (0,
absent; 1, weak; 2, moderate; and 3, strong); (b) the proportion of
malignant cells positively stained was scored from 0 to 4 (0, no
positive cells; 1, , 10% positive cells; 2, 11–50%; 3, 51–75%; and
4, 76–100%). The two scores were then added to yield the total
score (0–7). Immunoreactivity was defined as negative when the
score was 0, weak when it was 1–3, and strong when it was . 4.
Tumours with scores ranging from 2 to 7 were considered as
positive. Appropriate controls were included in every experiment.
Previous studies (Basolo et al, 1993a) had shown that the sensi-
tivity of immunostaining for IL-6 with the two antibodies used in
this study was high. We have now shown that cytoplasmic posi-
tivity is maintained even in cultured cells releasing as little as
100–200 pg of IL-6 per 106 cells. As specificity controls, we
showed that immunostaining of mammary tissue sections by IL-6
antibodies was blocked by incubation with recombinant IL-6
(Genzyme; 300 ng cytokine 1 1 mg antibody in 100 ml for 6 h),
but not with equivalent amounts of recombinant IL-2 or IL-8
(Genzyme).
Ki67 labelling index
The nuclear proliferation-associated antigen Ki67 was assayed on
frozen sections using the Ki67 mouse monoclonal antibody (Dako
A/S) diluted 1:10 in phosphate-buffered saline (PBS) and incu-
bated overnight. Immunoreactivity was revealed as stated above.
Negative control sections were incubated with normal mouse
serum. As previously reported (Campani et al, 1991), the evalua-
tion of Ki67 was expressed as the percentage of positive cells. For
each tumour section, at least 25 microscopic fields (40 3 objec-
tive) were analysed. The percentage was calculated dividing the
number of Ki67-positive neoplastic cells by the total number of
cells counted, and the result multiplied by 100. Tumours were
classified as highly proliferating if more than 10% (median value
of the distribution) of cells were immunoreactive (Campani et al,
1991).
Hormone receptor analysis
The presence of oestrogen receptor (ER) was determined using the
Abbott ER-ICA monoclonal kit (Abbott Laboratories, Abbott
Park, MI, USA), as described (Campani et al, 1991). Briefly, rat
anti-human ER antibody was incubated with frozen sections
followed by a goat anti-rat IgG and revealed with a rat peroxi-
dase–anti-peroxidase complex. Peroxidase activity was detected
by the incubation of the antibody complex with 3,3¢-diamino-
benzidine and hydrogen peroxide. Expression of progesterone
receptor (PR) was determined by the same method as ER, using
the Abbott PR-ICA monoclonal kit (Abbott Laboratories).
Negative controls were incubated with normal rat serum. ER and
PR expression was quantitated as a percentage value as described
for Ki67. Tumours with ≤ 5% positive cells were classified as
negative.
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Table 1 Association between IL-6 expression and clinico-pathological
parameters in breast cancer
Feature IL-6 expressiona
No Negative Positive Pb
Histotype
Ductal infiltrating 121 20 101
Lobular infiltrating 22 4 18
Medullary carcinoma 6 2 4
Pathological tumour size
pT1 80 14 66
pT2–3 64 13 51 NS
NKc 5
Histological grading
I2 5 0 2 5
II/III 96 20 76 0.0017
No. of involved nodes
07 9 1 7 6 2
, 3 32 4 28 NS
. 3 31 5 26 NS
NK 7
aTumours with scores of 0 and 1 were considered as negative; tumours with
scores ranging from 2 to 7 were considered as positive. bStatistical analysis:
c2 with Fisher’s correction (the NK group as not included). cNK, not known.
Table 2 Association between IL-6 expression and biological parameters in
breast cancers
Feature IL-6 expressiona
No Negative Positive Pb
p53 expression
Negative 117 22 95
Positive 33 5 28 NS
ER expressionc
Negative 50 14 36
Positive 94 11 83 0.02
NKd 5
PR expressionc
Negative 50 10 40
Positive 52 5 47 NS
NK 47
Ki67 expressione
Low 19 6 13
High 44 6 38 NS
NK 86
aTumours with scores of 0 and 1 were considered as negative; tumours with
scores ranging from 2 to 7 were considered as positive. bStatistical analysis:
c2 with Fisher’s correction (the NK group was not included). cTumours with
≤5% positive cells were considered as negative; tumours with . 5% positive
cells were considered as positive. dNK, not known. eLow expression means
≤10% of positive cells; high expression, means . 10% of cells.Histological grading
Cases selected for this study were reviewed by two pathologists
(FB and GF) and classified according to a recent modification of
the WHO Histological Classification of Breast Tumours (Rosen
and Oberman, 1993). The Scarff, Bloom and Richardson histo-
prognostic grade was scored according to the Contesso recommen-
dations (Contesso et al, 1987) by evaluating three parameters:
tubular differentiation (throughout, 1; occasional, 2; not seen, 3),
nuclear polymorphism (uniform and regular size, 1; moderate
pleomorphism, 2; very pleomorphic, 3) and mitotic index (1
mitosis, 1; 2, 2; 3, 3). The final grade is determined by adding the
three scores: grade 1, 3–5; grade 2, 6–7; grade 3, 8–9.
Statistical methods
A c2 test with Fisher’s correction was used for the correlating
clinico-pathological parameters with IL-6 immunoreactivity. For
continuous variables, Sperman’s test was used to analyse the
correlation between the percentages of IL-6-positive cells and
positivity for p53, ER, PR and K67.
RESULTS
IL-6 protein expression
The histotype of all cases was determined according to the widely
accepted criteria of Rosen and Oberman (Rosen and Oberman,
1993). IL-6 expression was studied by immunostaining with poly-
clonal and monoclonal antibodies. Both reagents produced clear
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Figure 1 Immunohistochemical staining for IL-6 in invasive ductal
carcinoma. (A) Strong cytoplasmic immunoreactivity for IL-6 in the neoplastic
component of epithelial cells (original magnification, 3250). (B) High
magnification of neoplastic gland showing strong and specific
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Figure 2 Correlation between IL-6 expression and expression of p53, PR
and ER in breast carcinoma. The percentage of IL-6-positive cells in each
case was related to the positivity for p53, PR or ER. Statistical analysis was
performed by the Spearman test for continuous variables. No correlation was
found between IL-6 and p53 expression (r 52 0.042, t 52 0.51; P 5 0.6); a
direct correlation was observed between IL-6 expression and positivity for
both ER (r 5 0.381, t 5 3.7, P 5 0.00037) and PR (r 5 0.22, t 5 2.27; P 5
0.025)cytoplasmic reactivity, but the staining pattern produced by the
polyclonal rabbit antibody was more intense and reproducible
(Figure 1 A, B). Reactivity of both antibodies was totally abol-
ished by preincubation with recombinant-IL-6 (r-IL-6), but not
with either r-IL-2 or r-IL-8. The immunoreactivity of each tumour
was scored from 0 to 7 as reported in Materials and Methods. The
staining pattern was heterogeneous (i.e. in positive sections the
intensity of staining ranged from negative to strong). As reported
in Table 1, the majority of cases expressed immunoreactive IL-6
(82%). Among cases of IL-6-negative carcinoma, staining was
clearly limited to remaining normal ducts and lobules.
IL-6 expression in relation to clinico-pathological
parameters
In Table 1, patients were grouped according to IL-6-negativity and
IL-6-positivity. We analysed the data in relation to the following
clinico-pathological variables: tumour size, histological grade and
nodal status. A significant association was found between IL-6
expression and histological grading of the tumours; i.e. low-grade
tumours (grade I) had higher IL-6 expression than high-grade
tumours (grade II and III; P 5 0.0017). No statistically significant
association was, however, found between IL-6 expression and
tumour size or nodal status.
IL-6 expression in relation to p53, ER, PR and Ki67
p53 overexpression was observed in 33 (22%) out of 149 carci-
nomas analysed. However, no differences were observed in IL-6
expression between p53-positive and p53-negative cases (Table 2).
No correlation was detected by the Sperman’s test between p53 and
IL-6 expression (r 52 0.042, t 52 0.51, P 5 0.6). Interestingly,
among the 94 ER-positive carcinomas, 83 (88%) cases were IL-6-
positive, while among the 50 ER-negative tumours 36 (72%) were
IL-6-positive (P 5 0.02). This conclusion was confirmed by the
Sperman analysis that showed a significant direct correlation
between the percentage of IL-6-positive cells and the percentage of
ER-positive cells (r 5 0.381, t 5 3.7, P 5 0.00037). A significant
direct correlation was also found between PR and IL-6 expression
(r 5 0.22, t 5 2.27; P 5 0.025). On the contrary, an inverse corre-
lation was observed between IL-6 expression and the proliferative
index, as evaluated by Ki67 immunoreactivity (r 52 0.28, t 5
22.28, P 5 0.027). Figure 2 summarizes the statistical correlation
between IL-6, ER, PR and p53 expression.
DISCUSSION
Over the last few years, the role of cytokines in cancer has been
the subject of numerous investigations (Porter and Lippman,
1994). It has been reported that, in the mammary gland, cytokines
play a role in growth and differentiation (Massagué et al, 1992;
Basolo et al, 1993b; Danforth and Sagias, 1993), extracellular
matrix production (Silberstein et al, 1992), angiogenesis (Garver
et al, 1994) and as immunomodulating factors (Allione et al,
1994). Recently, we have shown that epithelial cells of the normal
mammary gland produce constitutively IL-6, IL-8 and a non-
secreted form of TNF (Basolo et al, 1993a). In addition, we
observed that upon transformation in vitro by several different
oncogenes (except for int-2), MEC lose the ability of producing
and responding to IL-6 (Basolo et al, 1993b).
It has also been demonstrated in vivo that, as compared to
normal mammary tissue, the expression of IL-6 in neoplastic
tissues is slightly reduced in non-invasive ductal carcinoma, but
strongly reduced in the invasive forms of ductal and medullary
carcinoma. This finding suggests an inverse relationship between
tumour aggressiveness and IL-6 expression, in agreement with
observations in tumours of the salivary gland (Gandour-Edwards
et al, 1995a) and thyroid (Basolo et al, 1998). These results have
been confirmed by experiments in vitro. Primary cultures from
ductal carcinomas produce reduced amounts of IL-6 as compared
to primary cultures obtained from the normal mammary gland
(Basolo et al, 1996b).
IL-6 expression appears to relate to prognosis in tumours other
than those of breast. An inverse relationship between IL-6 expres-
sion and biological aggressiveness has been reported in salivary
gland tumours (Gandour-Edwards et al, 1995a), malignant
melanoma cells have been shown to be unresponsive to exogenous
IL-6 (Lu and Kerbel, 1993; Silvani et al, 1995), invasive pituitary
malignancies appear to overexpress IL-6 (Gandour-Edwards et al,
1995b). In ovarian cancer patients, IL-6 serum levels have been
correlated with a poor prognosis, since patients with low IL-6
levels had better survival than patients with high levels of this
cytokine (Scambia et al, 1995). The above results prompted us to
investigate whether alterations of IL-6 expression were correlated
with tumour aggressiveness as evaluated by clinico-pathological
and biological parameters. Although no association was observed
between IL-6 expression and tumour size or nodal status, a statisti-
cally significant association was found with the histological grade
of tumours. Approximately one-fifth (25/121) of investigated
ductal carcinomas were classified as grade I. None of these 25
well-differentiated tumours was IL-6-negative. On the contrary,
20/96 (21%) grade II or III ductal carcinomas were IL-6-negative.
Since high grade indicates less differentiated tumours, this finding
suggests that reductions of IL-6 expression are associated with late
stages of tumorigenesis. This was confirmed by the observation
that highly proliferating tumours (as evaluated by Ki67 immuno-
reactivity) were characterized by low percentages of IL-6-positive
cells (r 52 0.28, t 52 2.28, P 5 0.027). Other interesting corre-
lations of IL-6 expression with other biological parameters (ER,
PR) were detected.
On the contrary, IL-6 expression was directly correlated with
the expression of ERs and PRs that represent important mammary
differentiation markers. Eighty-three out of 94 (88%) ER-positive
tumours were also reactive with antibody to IL-6 (P 5 0.02; Table
2), and the percentage of ER-positive cells was directly related to
that of IL-6-positive cells (P 5 0.00005; Figure 2). Equivalent
results were obtained with regard to the percentages of PR-posi-
tive cells (P 5 0.025; Figure 2). The potential interaction between
cytokines and steroid hormones has already been suggested by
studies of breast cyst fluid (Reed et al, 1992). It was observed that
IL-1 and IL-6 do increase oestrogen synthesis by stimulating
aromatase and oestradiol-dehydrogenase activities in breast cancer
cells. In addition, it has been reported that ER-positive human
breast cancer cells express the IL-6 receptor and that their prolifer-
ation is inhibited by addition of IL-6 (Chen et al, 1988; Chiu et al,
1996). In experiments in vitro we found that insertion of the int-2
gene into MEC results in the up-regulation of IL-6-receptor thus
promoting cell proliferation in response to exogenous IL-6 and
glucocorticoids (Basolo et al, 1993a). Taken together, these results
indicate a possible autocrine and/or paracrine role of IL-6 at least
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receptor. The existence of a complex interplay between IL-6 path-
ways and steroid hormones is further exemplified by the finding
that in human osteoblasts the IL-6 promoter is inhibited by
oestrogen in the absence of a functional ER binding site (Stein and
Yang, 1995). In conclusion, it appears that IL-6 is capable of
modulating steroid hormone responsiveness and vice-versa.
Overexpression of the p53 protein has been correlated with poor
patient prognosis in breast cancer (Stenmark-Askmalm et al, 1995;
Horne et al, 1996), indicating that p53 represents an important
prognostic marker. However, in this study we failed to detect
correlations between p53 overexpression and IL-6 expression
(Table 2, P 5 0.2; Figure 2, P 5 0.6). It is of interest to note that
p53 appears to modulate IL-6 expression. Experiments in HeLa
cells demonstrated that the IL-6 promoter is repressed by wild-
type p53 and up-regulated by mutant forms (Margulies et al, 1993;
Stenmark-Askmalm et al, 1995).
Since MEC constitutively produce not only IL-6, but also IL-8
and a non-secreted form of TNF, further studies are needed to
ascertain if the expression of the ER and PR differentiation
markers is also associated with altered expression of the above
cytokines. In this context it should be recalled that Fas (APO-
1/CD95) is expressed on the surface of normal and transformed
MEC (Keane et al, 1996) and that interaction of Fas with ligands
of the TNF family may trigger programmed cell death (Hug,
1997). It will be of interest to evaluate whether Fas expression is
downregulated in high grade mammary tumours as a means of
escaping the apoptotic response as already reported for colon
carcinoma (von Reyhet et al, 1998).
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